Base Therapeutics has successfully completed its Series A2 financing round, securing tens of millions of RMB. The funding, led by the AEF Greater Bay Area Fund and managed by Gobi Partners GBA, will be allocated to enhance Base Therapeutics’ R&D team, refine its product pipeline, speed up clinical trials, and support future commercialization efforts.
Base Therapeutics was founded in 2021 and is a technology-driven innovative enterprise focusing on foundational innovations in gene editing. It is a global pioneer in base editing and cell gene therapy research and development. Since its inception, the company has been committed to developing world-first cell therapies and gene editing products, particularly showing great promise in treating cancers and genetic diseases.
Base Therapeutics has pioneered several key technologies in gene editing, including ePE lead editing, the AccuBase® base editing system, CasH gene editing technology, BEAT-CART technology, and in vivo targeted delivery technology. Notably, the AccuBase base editing system offers globally free-to-operate (FTO) capabilities, allowing for precise and off-target-free gene editing both in vitro and in vivo. It is also the world’s first base editing-targeted NK cell therapy product, using base editing to enhance the specificity of NK cells.
The company has established a nearly 2,500-square-meter GMP cell production facility, designed to meet clinical-grade standards for cell therapy research and production. Base Therapeutics' pipeline features various base-edited NK cell products aimed at treating hematological malignancies and autoimmune diseases, as well as universal CAR immunotherapy products and in vivo gene editing technologies.
In terms of external collaborations, Base Therapeutics has licensed its AccuBase base editing technology non-exclusively to leading CAR-T cell therapy companies internationally. The company also collaborates with agricultural enterprises to develop thornless fish using base editing technology and explores applications in crop improvement and livestock genetic modification.
Base Therapeutics has secured tens of millions of dollars in seed and Series A funding from leading international biopharmaceutical venture capital firms. The company has earned several accolades, including second place in the national finals of the 12th China Innovation and Entrepreneurship Competition. Additionally, it holds 29 intellectual property applications, encompassing software copyrights, utility model patents, national invention patents, PCT, and US patents.
Dr. Tianhong Xu, Founder and CEO of Base Therapeutics, expressed enthusiasm about the strategic partnership with Gobi Partners GBA. “Gobi Partners GBA’s investment is a strong endorsement of Base Therapeutics’ groundbreaking gene editing technology and our team’s vision to revolutionize healthcare. With their deep understanding of the Greater Bay Area market and extensive global network, we are confident in accelerating our expansion into Hong Kong and beyond. This partnership is instrumental in advancing our clinical trials, forging strategic collaborations, and ultimately delivering life-changing therapies to patients worldwide”.
As Fred Li, Senior Executive Director of Gobi Partners GBA noted, “Base Therapeutics is a promising investment opportunity in the Greater Bay Area. Their groundbreaking work in gene editing aligns with our focus on supporting cutting-edge healthcare technologies. We are confident that their expansion into Hong Kong will further strengthen their position in the global healthcare technology market and drive innovation”.